| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
40,450,000 |
| Market
Cap: |
1.35(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$18.17 - $33.65 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Kiniksa Pharmaceuticals is a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients suffering from debilitating diseases with unmet medical need. Co.'s portfolio of assets include: ARCALYST® (rilonacept) is for the treatment of Cryopyrin-Associated Periodic Syndrome; mavrilimumab is targeting granulocyte-macrophage colony stimulating factor receptor alpha; vixarelimab is evaluating vixarelimab for the potential treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404 is a humanized monoclonal antibody that is designed to inhibit the CD40-CD154 interaction.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
677,835 |
971,390 |
1,361,757 |
1,739,425 |
| Total Sell Value |
$21,108,487 |
$28,493,481 |
$37,761,255 |
$46,409,324 |
| Total People Sold |
8 |
8 |
8 |
8 |
| Total Sell Transactions |
23 |
42 |
59 |
75 |
| End Date |
2025-05-18 |
2025-02-14 |
2024-08-16 |
2023-08-17 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Malley Thomas |
|
– • – |
2025-08-14 |
4 |
S |
$33.09 |
$2,588,730 |
D/D |
(78,233) |
12,546 |
|
- |
|
| Malley Thomas |
|
– • – |
2025-08-14 |
4 |
OE |
$14.33 |
$1,165,028 |
D/D |
78,233 |
90,779 |
|
- |
|
| Malley Thomas |
|
– • – |
2025-08-13 |
4 |
S |
$33.32 |
$1,670,298 |
D/D |
(50,129) |
12,546 |
|
1% |
|
| Malley Thomas |
|
– • – |
2025-08-13 |
4 |
OE |
$9.88 |
$504,936 |
D/D |
50,129 |
62,675 |
|
- |
|
| Malley Thomas |
|
– • – |
2025-08-12 |
4 |
S |
$32.40 |
$1,600,787 |
D/D |
(49,407) |
12,546 |
|
-2% |
|
| Malley Thomas |
|
– • – |
2025-08-12 |
4 |
OE |
$1.86 |
$145,146 |
D/D |
49,407 |
61,953 |
|
- |
|
| Paolini John F. |
CHIEF MEDICAL OFFICER |
• – – |
2025-08-06 |
4 |
AS |
$32.55 |
$954,529 |
D/D |
(29,325) |
57,403 |
|
-2% |
|
| Paolini John F. |
CHIEF MEDICAL OFFICER |
• – – |
2025-08-06 |
4 |
OE |
$3.80 |
$111,435 |
D/D |
29,325 |
86,728 |
|
- |
|
| Tessari Eben |
CHIEF OPERATING OFFICER |
• – – |
2025-08-05 |
4 |
AS |
$33.20 |
$4,602,370 |
D/D |
(138,614) |
49,915 |
|
-3% |
|
| Tessari Eben |
CHIEF OPERATING OFFICER |
• – – |
2025-08-05 |
4 |
OE |
$10.36 |
$1,585,652 |
D/D |
138,614 |
188,529 |
|
- |
|
| Ragosa Mark |
CHIEF FINANCIAL OFFICER |
• – – |
2025-08-04 |
4 |
AS |
$32.89 |
$621,259 |
D/D |
(18,889) |
27,009 |
|
-2% |
|
| Ragosa Mark |
CHIEF FINANCIAL OFFICER |
• – – |
2025-08-04 |
4 |
OE |
$22.89 |
$432,369 |
D/D |
18,889 |
45,898 |
|
- |
|
| Megna Michael R |
CHIEF ACCOUNTING OFFICER |
• – – |
2025-08-04 |
4 |
AS |
$32.35 |
$549,950 |
D/D |
(17,000) |
33,041 |
|
-2% |
|
| Megna Michael R |
CHIEF ACCOUNTING OFFICER |
• – – |
2025-08-04 |
4 |
OE |
$15.52 |
$263,840 |
D/D |
17,000 |
50,041 |
|
- |
|
| Popovits Kimberly J |
|
– • – |
2025-07-30 |
4 |
OE |
$29.90 |
$1,928,789 |
D/D |
64,508 |
12,546 |
|
- |
|
| Popovits Kimberly J |
|
– • – |
2025-07-30 |
4 |
OE |
$10.36 |
$764,166 |
D/D |
64,508 |
77,054 |
|
- |
|
| Tessari Eben |
CHIEF OPERATING OFFICER |
• – – |
2025-07-15 |
4 |
A |
$15.63 |
$11,754 |
D/D |
752 |
49,915 |
|
- |
|
| Megna Michael R |
CHIEF ACCOUNTING OFFICER |
• – – |
2025-07-15 |
4 |
A |
$15.63 |
$7,737 |
D/D |
495 |
33,041 |
|
- |
|
| Tessari Eben |
CHIEF OPERATING OFFICER |
• – – |
2025-07-14 |
4 |
AS |
$28.72 |
$542,808 |
D/D |
(18,900) |
49,163 |
|
12% |
|
| Tessari Eben |
CHIEF OPERATING OFFICER |
• – – |
2025-07-14 |
4 |
OE |
$8.83 |
$57,395 |
D/D |
6,500 |
68,063 |
|
- |
|
| Levy Richard S |
|
– • – |
2025-07-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,101 |
18,474 |
|
- |
|
| Tessari Eben |
CHIEF OPERATING OFFICER |
• – – |
2025-06-16 |
4 |
AS |
$28.28 |
$489,244 |
D/D |
(17,300) |
61,563 |
|
13% |
|
| Tessari Eben |
CHIEF OPERATING OFFICER |
• – – |
2025-06-16 |
4 |
OE |
$8.83 |
$57,395 |
D/D |
6,500 |
78,863 |
|
- |
|
| Quart Barry D |
|
– • – |
2025-06-11 |
4 |
S |
$30.39 |
$374,891 |
D/D |
(12,336) |
12,546 |
|
-10% |
|
| Quart Barry D |
|
– • – |
2025-06-11 |
4 |
OE |
$3.80 |
$46,877 |
D/D |
12,336 |
24,882 |
|
- |
|
453 Records found
|
|
Page 1 of 19 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.10 (0.3%) 
